Cover Image
市場調查報告書

Nektar Therapeutics:產品平台分析

Nektar Therapeutics - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 224601
出版日期 內容資訊 英文 57 Pages
訂單完成後即時交付
價格
Back to Top
Nektar Therapeutics:產品平台分析 Nektar Therapeutics - Product Pipeline Review - 2016
出版日期: 2016年04月27日 內容資訊: 英文 57 Pages
簡介

Nektar Therapeutics是為了克服未滿足需求,基於PEGylation及先進的高分子共軛技術平台開發新治療藥候補的開發平台生物科技企業。

本報告提供Nektar Therapeutics的治療藥開發平台現狀及各開發階段的比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,彙整最新的企業新聞和發表,後期階段及中止的計劃相關資訊等。

Nektar Therapeutics的基本資料

Nektar Therapeutics概要

  • 主要資訊
  • 企業資料

Nektar Therapeutics:R&D概要

  • 主要的治療範圍

Nektar Therapeutics:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

Nektar Therapeutics:開發中產品概況

  • 最後階段的開發中產品
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Nektar Therapeutics:藥物簡介

  • etirinotecan pegol
  • NKTR-181
  • NKTR-171
  • NKTR-125
  • NKTR-140
  • NKTR-174
  • NKTR-192
  • NKTR-194
  • NKTR-195
  • NKTR-196
  • NKTR-214
  • NKTR-223
  • NKTR-228
  • 抗病毒細胞激素
  • 腫瘤細胞激素
  • 腫瘤葉酸抑制劑
  • 激酶抑制劑等

Nektar Therapeutics:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Nektar Therapeutics:最近的開發平台趨勢

Nektar Therapeutics:暫停中的計劃

Nektar Therapeutics:開發中止的開發中產品

  • 開發中止的開發中產品簡介
    • NKTR-105
    • NKTR-192

Nektar Therapeutics:企業發表

Nektar Therapeutics:總公司和子公司的所在地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08036CDB

Summary

Global Markets Direct's, 'Nektar Therapeutics - Product Pipeline Review - 2016', provides an overview of the Nektar Therapeutics's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Nektar Therapeutics, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Nektar Therapeutics
  • The report provides overview of Nektar Therapeutics including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Nektar Therapeutics's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Nektar Therapeutics's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Nektar Therapeutics's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Nektar Therapeutics
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Nektar Therapeutics's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Nektar Therapeutics Snapshot
    • Nektar Therapeutics Overview
    • Key Information
    • Key Facts
  • Nektar Therapeutics - Research and Development Overview
    • Key Therapeutic Areas
  • Nektar Therapeutics - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Nektar Therapeutics - Pipeline Products Glance
    • Nektar Therapeutics - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Nektar Therapeutics - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Nektar Therapeutics - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Nektar Therapeutics - Drug Profiles
    • etirinotecan pegol
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NKTR-181
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NKTR-214
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NKTR-171
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NKTR-173
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NKTR-195
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NKTR-218
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NKTR-223
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NKTR-230
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NKTR-255
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Proteins for Hematological Disorders
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drug to Inhibit Kinase for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Protein to Agonize Cytokine Receptor for Inflammation
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Protein to Agonize Cytokine Receptor for Viral Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Nektar Therapeutics - Pipeline Analysis
    • Nektar Therapeutics - Pipeline Products by Target
    • Nektar Therapeutics - Pipeline Products by Route of Administration
    • Nektar Therapeutics - Pipeline Products by Molecule Type
    • Nektar Therapeutics - Pipeline Products by Mechanism of Action
  • Nektar Therapeutics - Recent Pipeline Updates
  • Nektar Therapeutics - Dormant Projects
  • Nektar Therapeutics - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • NKTR-105
      • NKTR-192
  • Nektar Therapeutics - Company Statement
  • Nektar Therapeutics - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Nektar Therapeutics, Key Information
  • Nektar Therapeutics, Key Facts
  • Nektar Therapeutics - Pipeline by Indication, 2016
  • Nektar Therapeutics - Pipeline by Stage of Development, 2016
  • Nektar Therapeutics - Monotherapy Products in Pipeline, 2016
  • Nektar Therapeutics - Partnered Products in Pipeline, 2016
  • Nektar Therapeutics - Partnered Products/ Combination Treatment Modalities, 2016
  • Nektar Therapeutics - Out-Licensed Products in Pipeline, 2016
  • Nektar Therapeutics - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • Nektar Therapeutics - Phase III, 2016
  • Nektar Therapeutics - Phase II, 2016
  • Nektar Therapeutics - Phase I, 2016
  • Nektar Therapeutics - Preclinical, 2016
  • Nektar Therapeutics - Discovery, 2016
  • Nektar Therapeutics - Pipeline by Target, 2016
  • Nektar Therapeutics - Pipeline by Route of Administration, 2016
  • Nektar Therapeutics - Pipeline by Molecule Type, 2016
  • Nektar Therapeutics - Pipeline Products by Mechanism of Action, 2016
  • Nektar Therapeutics - Recent Pipeline Updates, 2016
  • Nektar Therapeutics - Dormant Developmental Projects,2016
  • Nektar Therapeutics - Discontinued Pipeline Products, 2016
  • Nektar Therapeutics, Other Locations
  • Nektar Therapeutics, Subsidiaries

List of Figures

  • Nektar Therapeutics - Pipeline by Top 10 Indication, 2016
  • Nektar Therapeutics - Pipeline by Stage of Development, 2016
  • Nektar Therapeutics - Monotherapy Products in Pipeline, 2016
  • Nektar Therapeutics - Out-Licensed Products in Pipeline, 2016
  • Nektar Therapeutics - Pipeline by Target, 2016
  • Nektar Therapeutics - Pipeline by Route of Administration, 2016
  • Nektar Therapeutics - Pipeline by Molecule Type, 2016
  • Nektar Therapeutics - Pipeline Products by Mechanism of Action, 2016
Back to Top